VRTV Research Update — October 1, 2026
Updated Thesis
Veritiv Corporation is a business-to-business distributor of packaging, facility solutions, print, and publishing products, operating through four segments with roughly 5,000 employees and a legacy network of distribution centers. The business quality is mixed: a 48.6% ROE and $16.27 in free cash flow per share show real cash generation, but the most recent quarter brought a 19.0% year-over-year revenue decline and a 37.1% year-over-year earnings decline, with TTM operating margin of 5.9% and net margin of 4.7% leaving thin cushion. At $169.99, the shares trade at 7.13 times trailing earnings, 10.45 times free cash flow, and 5.44 times EV/EBITDA, yet our blended fair value estimate is $93.49, implying 45.0% downside to fair value and an 81.8% premium to that estimate, and the stock sits in a very_expensive regime relative to its own five-year history.
The investment grade as of this refresh is D — solid business quality. C-tier business, D-tier valuation: 45.0% downside to $93.49 fair value.
Key Metrics at a Glance
- Revenue growth: -19.0% year over year
- Net margin: 4.7%
- Fair value upside: -45.0% to our estimate of $93
Current price: $169.99
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Veritiv Corporation remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full VRTV research →](/stocks/VRTV)